Zopiclone

Caution is advised in patients with respiratory insufficiency given the GABA-A modulator mechanism. Published polysomnographic data show no detrimental respiratory effects at the therapeutic 7.5 mg dose in healthy subjects, but specific data in COPD and obstructive sleep apnea populations are limited.

Class-level contraindication for all GABA-A PAMs. Zopiclone's muscle relaxant properties may worsen symptoms in myasthenia gravis patients. Zopiclone-specific data not available.

Patients with a history of substance use disorder are at elevated risk of developing dependence on zopiclone. EudraVigilance data confirm dependence risk equivalent to zolpidem. Abuse and misuse have been documented in addiction service populations. Particular caution or avoidance is warranted.

Severe liver disease significantly alters zopiclone pharmacokinetics: bioavailability increases to ~97%, Tmax is delayed to ~3.5 hours, and elimination half-life extends to ~8.4 hours. Dose reduction to 3.5 mg is mandatory. CYP3A4 is the principal metabolic enzyme.

Zopiclone distributes into breast milk with milk and plasma kinetics following similar profiles. At a milk/plasma ratio of ~0.80, nursing infants receive clinically meaningful exposure to a CNS depressant. Breastfeeding is contraindicated during zopiclone use.

Zopiclone safety in human pregnancy has not been established. Given documented excretion in breast milk at substantial concentrations, fetal exposure during pregnancy is presumed. Animal reproductive toxicity data exist but human data are absent.

Pharmacokinetics are significantly altered in elderly patients: bioavailability increases up to ~168% of young-adult values, elimination half-life extends to ~8.1 hours. Dose reduction from 7.5 mg to 3.75 mg is mandatory. Falls risk, cognitive impairment, and paradoxical behavioral effects are elevated in this population.

Co-administration with alcohol, opioids, benzodiazepines, antipsychotics, sedating antihistamines, or sedating antidepressants produces additive CNS depression. Polydrug overdose involving zopiclone and other CNS depressants is the principal context for fatality. Pharmacokinetic parameters are not altered by alcohol, but pharmacodynamic effects are clearly additive.

Documented residual impairment of psychomotor performance, cognitive function, and highway driving ability persists up to 10 hours after a standard 7.5 mg oral dose. Zopiclone is used as the standard positive control in clinical driving impairment trials specifically because of this reliable, prolonged residual effect. Patients must avoid driving or operating machinery for at least 8-10 hours post-dose.